Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

BelgiumBack to Belgium

Clinical trials in Gent – page 13

899 clinical trials in Gent, Belgium across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gent at a glance
899
clinical trials
  • Research sites6
Type of trial
Recruitment status
Quick filters

899 trials in Gent

Open in trial search

Astrocytoma malignant

Recruiting

Vorasidenib for patients with IDH-mutant grade 2 or 3 astrocytoma after completing first-line chemoradiotherapy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Vorasidenib
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Renal cell carcinoma

Recruiting

A Study of Belzutifan and Zanzalintinib Compared to Cabozantinib in Patients with Advanced Kidney Cancer that Returned After Previous Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer metastatic

Recruiting

Study of Different Dosing Schedules of Osimertinib in Patients with EGFR Mutated Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Endometrial cancer+1

Recruiting

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Db-1303
  • Sponsor:BioNTech SE

Malignant mast cell neoplasm

Recruiting

Study of BNT326 alone and with BNT327 in patients with advanced solid tumors: Testing safety and effectiveness of new cancer treatments

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BNT327
  • Sponsor:BioNTech SE

Spinal muscular atrophy

Recruiting

Study of Apitegromab Treatment in Children Under 2 Years Old with Spinal Muscular Atrophy (SMA)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Apitegromab
  • Sponsor:Scholar Rock Inc.

PIK3CA related overgrowth spectrum

Recruiting

Study of alpelisib in children and adults with PIK3CA-Related Overgrowth Spectrum (PROS)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Postoperative analgesia

Recruiting

Study of Ropivacaine for Pain Control in Patients Having Open Heart Surgery Through Chest Bone Incision

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:UZ Leuven

Papilloma viral infection

Recruiting

Study of HPV antibody response in urine samples before and after HPV 9-valent vaccine in people with Human Papillomavirus infection

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Human Papillomavirus Type 11 L1 Protein - Adsorbed - In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
  • Sponsor:University Of Antwerp

Ischaemic stroke

Recruiting

Study of alteplase and tenecteplase for intravenous thrombolysis in patients with ischemic stroke who are taking direct oral anticoagulants

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:Insel Gruppe AG

Chronic graft versus host disease

Recruiting

Study of belumosudil in children aged 1 to 18 years with moderate to severe chronic graft versus host disease requiring systemic treatment

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Belumosudil Mesilate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Triple negative breast cancer

Recruiting

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Belgium

The busiest research cities in the country

All 170 cities in Belgium

Clinical research in Gent

What the registry says about research in the country

01 Immunology and Vaccines

Multiple clinical trials focusing on vaccine development for various infectious diseases including influenza, RSV, and cytomegalovirus. Studies evaluating immune responses in both healthy volunteers and specific populations.

  • Influenza vaccine studies for adults 65+
  • RSV vaccine development
  • Varicella vaccine for children

Research includes evaluation of vaccine safety, immunogenicity, and effectiveness across different age groups.

02 Respiratory Medicine

Innovative research targeting chronic respiratory conditions and nasal health, including studies on rhinitis medicamentosa and chronic rhinosinusitis.

  • Nasal decongestant dependency treatment
  • Chronic rhinosinusitis management
  • Respiratory virus prevention

Trials focus on both therapeutic interventions and long-term disease management strategies.

03 Autoimmune and Inflammatory Conditions

Studies examining new treatments for inflammatory diseases including psoriasis, psoriatic arthritis, and biliary conditions.

  • Primary biliary cholangitis treatment
  • Psoriasis therapies
  • Immune system disorders

Research aims to improve treatment outcomes and quality of life for patients with chronic conditions.

Back to BelgiumAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.